Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about PHA: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| iPSC-NPC effects on astrocytes in vitro ICH model | exploratory | intracerebral hemorrhage | 0.900 | 0.00 | in vitro ICH cell culture mode | proposed | N/A |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| Irisin effects on osteogenic differentiation in mesenchymal stem cells | exploratory | bone fracture | 0.900 | 0.00 | mouse bone mesenchymal stem ce | proposed | N/A |
| AMPK knockdown validation experiment | exploratory | intracerebral hemorrhage | 0.880 | 0.00 | astrocyte cell culture | proposed | N/A |
| P2RY12-MTOR pathway interaction in VSMCs | exploratory | atherosclerosis | 0.850 | 0.00 | cultured VSMCs | proposed | N/A |
| iPSC-NPC transplantation in ICH animal model | validation | intracerebral hemorrhage | 0.850 | 0.00 | animal ICH model | proposed | N/A |
| Autophagy Enhancement Drug Screening for Neurodegeneration | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Chaperone-Mediated Autophagy Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Macroautophagy Dysfunction in PD - Experiment Design | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Validate Mitochondria-Lysosome Contact Site Dysfunction in PD | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic Target Val | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,000,000 |
| MLCS Quantification in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,730,000 |
| Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Ther | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| TMEM106B Haplotype as Genetic Modifier in FTD — Mechanism and Therapeu | validation | Neurodegeneration | 0.400 | 0.50 | human | proposed | $2,730,000 |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,900,000 |
| DLB Cognitive Fluctuation Mechanism Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868] | Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X | Pharmacol Rep | 2025 | 1 |
| Hepatocyte FoxO1 Deficiency Protects From Liver Fibrosis via Reducing Inflammati [PMID:37678798] | Pan Q, Gao M, Kim D, Ai W, Yang W, Jiang | Cell Mol Gastroenterol Hepatol | 2024 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and inv [PMID:35176466] | Zhang L, Liang B, Xu H, Gong Y, Hu W, Ji | J Ethnopharmacol | 2022 | 1 |
| Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662] | Dashti HS, Daghlas I, Lane JM, Huang Y, | Nat Commun | 2021 | 1 |
| Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813] | Sun Y, Tisdale RK, Kilduff TS | Front Neurol Neurosci | 2021 | 1 |
| Metformin Improves Mitochondrial Respiratory Activity through Activation of AMPK [PMID:31693892] | Wang Y, An H, Liu T, Qin C, Sesaki H, Gu | Cell Rep | 2019 | 1 |
| AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking Sy [PMID:30057310] | Song X, Zhu S, Chen P, Hou W, Wen Q, Liu | Curr Biol | 2018 | 1 |
| Obestatin controls the ubiquitin-proteasome and autophagy-lysosome systems in gl [PMID:28675664] | Cid-Díaz T, Santos-Zas I, González-Sánch | J Cachexia Sarcopenia Muscle | 2017 | 1 |
| Sleep drives metabolite clearance from the adult brain. [PMID:24136970] | Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th | Science | 2013 | 1 |
| PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tum [PMID:41920736] | Wang Z, Jin N, Li X, Ma X, Feng Y, Yin K | Cell reports | 2026 | 0 |
| Replating Induces mTOR-Dependent Rescue of Protein Synthesis in Charcot-Marie-To [PMID:41876253] | Koenig J, McGuire A, Homedan Y, Alberhas | eNeuro | 2026 | 0 |
| S-equol promotes ferroptosis in triple negative breast cancer by coordinating NC [PMID:41925800] | Ni F, Huang Z, Cui Y, Huang P, Xue Z, Hu | Molecular and cellular biochem | 2026 | 0 |
| Mammalian lipophagy: process and function. [PMID:41681129] | Zhao R, Dai E, Kang R, Liu J, Klionsky D | Autophagy | 2026 | 0 |
| TAZ alleviates ischemic stroke injury by activating Foxo1: Usp1-mediated deubiqu [PMID:41921828] | ["Xin Y", "Sun Y", "Pan E", "Li M", "Che | Free radical biology & medicin | 2026 | 0 |
| Metabolic dysregulation reshapes the immune landscape: The gut microbiota-mTOR a [PMID:41445190] | Li J, Li J, Chen K | Mol Ther | 2026 | 0 |
| Senecavirus a VP2 protein orchestrates PRDX1 degradation through dual autophagy [PMID:41479169] | Li Z, Yang X, Mao J, Zeng P, Qi Y et al. | Autophagy | 2026 | 0 |
| Inhibition of mTOR Enhances the Efficacy of Proteasome-Dependent Targeted Protei [PMID:41529091] | Liu Y, Sun Y, Song TY, Ni SY, Pu YS et a | Cancer Res | 2026 | 0 |
| Microglial metabolic reprogramming in Alzheimer's disease: Pathways, mechanisms, [PMID:41651180] | Yang FG, Yang H, Han SW, Wang JT, Gao W | Ageing Res Rev | 2026 | 0 |
| Combining network pharmacology and multi-omics reveals the role of Shengdihuang- [PMID:41655545] | Cao X, Shang Y, Qu M, Kang Q, Xu Y et al | Phytomedicine | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning PHA in their description or question text
Score: 0.841 · neurodegeneration · 2026-04-02
## Mechanistic Overview Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation starts from the claim t
Score: 0.838 · neurodegeneration · 2026-04-17
## Mechanistic Overview Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-A
Score: 0.827 · Alzheimer's disease · 2026-04-16
## Mechanistic Overview Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscillations via glymph
Score: 0.824 · neurodegeneration · 2026-04-17
## Mechanistic Overview SIRT1 Activation Couples Mitochondrial Biogenesis to Ferroptosis Suppression via PGC1alpha-Depen
Score: 0.822 · neurodegeneration · 2026-04-05
## Mechanistic Overview Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-
Score: 0.821 · neuroscience · 2026-04-07
## Mechanistic Overview Glymphatic-Mediated Tau Clearance Dysfunction starts from the claim that modulating MAPT within
Score: 0.820 · neurodegeneration · 2026-04-13
## Mechanistic Overview HSPB1 Phosphorylation Mimetics to Promote Protective TDP-43 Liquid-Liquid Phase Separation start
Score: 0.801 · neuroimmunology · 2026-04-15
## Mechanistic Overview CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification starts from the cl
Score: 0.796 · neurodegeneration · 2026-04-07
## Mechanistic Overview SASP-Driven Microglial Metabolic Reprogramming in Synaptic Phagocytosis starts from the claim th
Score: 0.787 · neurodegeneration · 2026-04-16
## Mechanistic Overview VCP-Mediated Autophagy Enhancement starts from the claim that modulating VCP within the disease
Score: 0.784 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophag
Score: 0.780 · neurodegeneration · 2026-04-22
## Mechanistic Overview Sleep-Dependent Glymphatic Clearance Expands the Therapeutic Window by Reducing Extracellular Ta
Score: 0.775 · Alzheimer's disease · 2026-04-12
## Mechanistic Overview Alpha-gamma cross-frequency coupling enhancement to restore thalamo-cortical memory circuits sta
Score: 0.773 · metabolic neuroscience · 2026-04-16
## Mechanistic Overview Biphasic Ketogenic Intervention Protocol starts from the claim that modulating HMGCS2 within the
Score: 0.772 · neurodegeneration · 2026-04-21
## Mechanistic Overview TBK1-OPTN-NDP52 Phospho-Cascade Coordinates Multi-Organelle Autophagy starts from the claim that